Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

2.370 +0.270 (+12.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,571,579
Open 2.110
Bid (Size) 3.500 (12)
Ask (Size) 3.510 (2)
Prev. Close 2.100
Today's Range 2.100 - 2.535
52wk Range 0.9001 - 2.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+22.16%
+22.16%
1 Month
+34.66%
+34.66%
3 Month
+22.80%
+22.80%
6 Month
+4.41%
+4.41%
1 Year
+35.43%
+35.43%

More News

Read More
A Preview Of Cognition Therapeutics's Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering
Via Investor Brand Network
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.